Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): Clinical, radiological and pathological characteristics in a French series.
HNF1A-MODY
diabetes mellitus
liver adenomatosis
糖尿病
肝细胞腺瘤病
Journal
Journal of diabetes
ISSN: 1753-0407
Titre abrégé: J Diabetes
Pays: Australia
ID NLM: 101504326
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
17
02
2019
revised:
13
05
2019
accepted:
30
05
2019
pubmed:
6
6
2019
medline:
9
6
2020
entrez:
6
6
2019
Statut:
ppublish
Résumé
Liver adenomatosis (LA) is a rare disease resulting from biallelic inactivation of the hepatocyte nuclear factor-1 alpha (HNF1A) gene, which induces the proliferation of adenoma cells in liver parenchyma. Liver adenomatosis has only been documented in case reports from patients carrying a HNF1A germline mutation. We have evaluated the frequency of LA among a large cohort of patients with HNF1A-maturity onset diabetes of the young (MODY), previously termed "MODY3," and herein describe its clinical, radiological, and pathological characteristics. In all, 137 HNF1A-MODY subjects from 74 families were screened by liver ultrasonography in 13 centers, and 15 additional cases of LA were later included in the series. Liver adenomatosis was confirmed by liver computed tomography, magnetic resonance imaging (MRI), and/or histopathology. Among 137 carriers of an HNF1A mutation, 9 patients (6.5%) from seven families were diagnosed with LA. Diabetes mellitus was present in 87.5% of patients with LA. In 25% of patients, LA was diagnosed due to intra-abdominal or intratumoral bleeding. Liver biochemistry was near normal in all patients. Liver imaging showed adenomas of various sizes and numbers. On MRI, most nodules had the radiological characteristics of steatotic adenomas. Histopathological confirmation of LA was available in 13 cases, and these adenomas were mostly steatotic. Surgery was initially performed in 37.5% of patients, and liver disease progression was observed in 30%. No disease progression was observed in 14 pregnancies. The frequency of LA in a cohort of screened HNF1A-MODY patients and the high incidence of LA progression and/or hemorrhage warrants systematic screening for liver adenomatosis in HNF1A-MODY families. 背景: 肝细胞腺瘤病(liver adenomatosis, LA)是一种由于肝细胞核因子-1α(HNF1A)基因中的双等位基因失活所导致的罕见疾病, 可诱发肝实质中的腺瘤细胞增殖。肝细胞腺瘤病仅见于携带HNF1A种系突变基因患者的病例报告。我们在一个大型HNF1A-青少年发病的成年型糖尿病(MODY, 以前被称为“MODY3”)患者队列中评估了LA的发生率, 并在此对其临床、放射学以及病理学特征进行了描述。 方法: 共有137名来自于74个家系的HNF1A-MODY受试者在13个中心接受了肝脏超声检查, 后续还有15名LA患者被纳入这项系列研究。通过肝脏计算机断层扫描、磁共振成像(MRI)和/或组织病理学检查来确诊肝细胞腺瘤病。 结果: 在137名HNF1A突变基因携带者中, 来自7个家系的9例(6.5%)患者被诊断为LA。87.5%的LA患者存在糖尿病。25%的患者因出现腹腔内或者肿瘤内出血而被诊断为LA。所有患者的肝脏生化指标均接近正常。肝脏影像学表现为大小不等、数目不等的腺瘤。在MRI上, 大多数结节具有脂肪性腺瘤的影像学特征。13例LA得到组织病理学证实, 并且这些腺瘤以脂肪变性为主。37.5%的患者最初进行了手术, 30%的患者观察到肝脏疾病进展。14例妊娠患者未见疾病进展。 结论: 在筛选的HNF1A-MODY患者队列中, 由于LA的高发病率以及LA进展和/或出血的高发生率, 因此很有必要在HNF1A-MODY家系中进行肝细胞腺瘤病的系统筛查。.
Sections du résumé
BACKGROUND
BACKGROUND
Liver adenomatosis (LA) is a rare disease resulting from biallelic inactivation of the hepatocyte nuclear factor-1 alpha (HNF1A) gene, which induces the proliferation of adenoma cells in liver parenchyma. Liver adenomatosis has only been documented in case reports from patients carrying a HNF1A germline mutation. We have evaluated the frequency of LA among a large cohort of patients with HNF1A-maturity onset diabetes of the young (MODY), previously termed "MODY3," and herein describe its clinical, radiological, and pathological characteristics.
METHODS
METHODS
In all, 137 HNF1A-MODY subjects from 74 families were screened by liver ultrasonography in 13 centers, and 15 additional cases of LA were later included in the series. Liver adenomatosis was confirmed by liver computed tomography, magnetic resonance imaging (MRI), and/or histopathology.
RESULTS
RESULTS
Among 137 carriers of an HNF1A mutation, 9 patients (6.5%) from seven families were diagnosed with LA. Diabetes mellitus was present in 87.5% of patients with LA. In 25% of patients, LA was diagnosed due to intra-abdominal or intratumoral bleeding. Liver biochemistry was near normal in all patients. Liver imaging showed adenomas of various sizes and numbers. On MRI, most nodules had the radiological characteristics of steatotic adenomas. Histopathological confirmation of LA was available in 13 cases, and these adenomas were mostly steatotic. Surgery was initially performed in 37.5% of patients, and liver disease progression was observed in 30%. No disease progression was observed in 14 pregnancies.
CONCLUSIONS
CONCLUSIONS
The frequency of LA in a cohort of screened HNF1A-MODY patients and the high incidence of LA progression and/or hemorrhage warrants systematic screening for liver adenomatosis in HNF1A-MODY families.
背景: 肝细胞腺瘤病(liver adenomatosis, LA)是一种由于肝细胞核因子-1α(HNF1A)基因中的双等位基因失活所导致的罕见疾病, 可诱发肝实质中的腺瘤细胞增殖。肝细胞腺瘤病仅见于携带HNF1A种系突变基因患者的病例报告。我们在一个大型HNF1A-青少年发病的成年型糖尿病(MODY, 以前被称为“MODY3”)患者队列中评估了LA的发生率, 并在此对其临床、放射学以及病理学特征进行了描述。 方法: 共有137名来自于74个家系的HNF1A-MODY受试者在13个中心接受了肝脏超声检查, 后续还有15名LA患者被纳入这项系列研究。通过肝脏计算机断层扫描、磁共振成像(MRI)和/或组织病理学检查来确诊肝细胞腺瘤病。 结果: 在137名HNF1A突变基因携带者中, 来自7个家系的9例(6.5%)患者被诊断为LA。87.5%的LA患者存在糖尿病。25%的患者因出现腹腔内或者肿瘤内出血而被诊断为LA。所有患者的肝脏生化指标均接近正常。肝脏影像学表现为大小不等、数目不等的腺瘤。在MRI上, 大多数结节具有脂肪性腺瘤的影像学特征。13例LA得到组织病理学证实, 并且这些腺瘤以脂肪变性为主。37.5%的患者最初进行了手术, 30%的患者观察到肝脏疾病进展。14例妊娠患者未见疾病进展。 结论: 在筛选的HNF1A-MODY患者队列中, 由于LA的高发病率以及LA进展和/或出血的高发生率, 因此很有必要在HNF1A-MODY家系中进行肝细胞腺瘤病的系统筛查。.
Autres résumés
Type: Publisher
(chi)
背景: 肝细胞腺瘤病(liver adenomatosis, LA)是一种由于肝细胞核因子-1α(HNF1A)基因中的双等位基因失活所导致的罕见疾病, 可诱发肝实质中的腺瘤细胞增殖。肝细胞腺瘤病仅见于携带HNF1A种系突变基因患者的病例报告。我们在一个大型HNF1A-青少年发病的成年型糖尿病(MODY, 以前被称为“MODY3”)患者队列中评估了LA的发生率, 并在此对其临床、放射学以及病理学特征进行了描述。 方法: 共有137名来自于74个家系的HNF1A-MODY受试者在13个中心接受了肝脏超声检查, 后续还有15名LA患者被纳入这项系列研究。通过肝脏计算机断层扫描、磁共振成像(MRI)和/或组织病理学检查来确诊肝细胞腺瘤病。 结果: 在137名HNF1A突变基因携带者中, 来自7个家系的9例(6.5%)患者被诊断为LA。87.5%的LA患者存在糖尿病。25%的患者因出现腹腔内或者肿瘤内出血而被诊断为LA。所有患者的肝脏生化指标均接近正常。肝脏影像学表现为大小不等、数目不等的腺瘤。在MRI上, 大多数结节具有脂肪性腺瘤的影像学特征。13例LA得到组织病理学证实, 并且这些腺瘤以脂肪变性为主。37.5%的患者最初进行了手术, 30%的患者观察到肝脏疾病进展。14例妊娠患者未见疾病进展。 结论: 在筛选的HNF1A-MODY患者队列中, 由于LA的高发病率以及LA进展和/或出血的高发生率, 因此很有必要在HNF1A-MODY家系中进行肝细胞腺瘤病的系统筛查。.
Identifiants
pubmed: 31166087
doi: 10.1111/1753-0407.12959
doi:
Substances chimiques
HNF1A protein, human
0
Hepatocyte Nuclear Factor 1-alpha
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
48-57Subventions
Organisme : Programme Hospitalier de Recherche Clinique 2004
ID : EudraCT no. 2004-R06
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Références
Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001;345:971-980.
Vaxillaire M, Pueyo ME, Clement K, et al. Insulin secretion and insulin sensitivity in diabetic and non-diabetic subjects with hepatic nuclear factor-1alpha (maturity-onset diabetes of the young-3) mutations. Eur J Endocrinol. 1999;141:609-618.
Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S. A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (HNF-1alpha) gene. Diabet Med. 1998;15:816-820.
Colclough K, Bellanne-Chantelot C, Saint-Martin C, Flanagan SE, Ellard S. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia. Hum Mutat. 2013;34:669-685.
Isomaa B, Henricsson M, Lehto M, et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia. 1998;41:467-473.
Bacq Y, Jacquemin E, Balabaud C, et al. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology. 2003;125:1470-1475.
Reznik Y, Dao T, Coutant R, et al. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY) 3 families. J Clin Endocrinol Metab. 2004;89:1476-1480.
Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology. 1985;89:1132-1138.
Chiche L, Dao T, Salame E, et al. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg. 2000;231:74-81.
Willson JS, Godwin TD, Wiggins GA, Guilford PJ, McCall JL. Primary hepatocellular neoplasms in a MODY3 family with a novel HNF1A germline mutation. J Hepatol. 2013;59:904-907.
Foster JH, Donohue TA, Berman MM. Familial liver-cell adenomas and diabetes mellitus. N Engl J Med. 1978;299:239-241.
Bluteau O, Jeannot E, Bioulac-Sage P, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet. 2002;32:312-315.
Jeannot E, Lacape G, Gin H, et al. Double heterozygous germline HNF1A mutations in a patient with liver adenomatosis. Diabetes Care. 2012;35:e35.
Pearson ER, Starkey BJ, Powell PJ, Gribble FM, Clarck PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362:1275-1281.
Colclough K, Saint-Martin C, Timsit J, Ellard S, Bellanne-Chantelot C. Clinical utility gene card for: maturity-onset diabetes of the young. Eur J Hum Genet. 2014;22:1153. https://doi.org/10.1038/ejhg.2014.14.
Lepreux S, Laurent C, Blanc JF, et al. The identification of small nodules in liver adenomatosis. J Hepatol. 2003;39:77-85.
Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford). 2005;7:186-196.
Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006;43:515-524.
Bioulac-Sage P, Sempoux C, Possenti L, et al. Pathological diagnosis of hepatocellular cellular adenoma according to the clinical context. Int J Hepatol. 2013;2013:253261.
Karkar AM, Tang LH, Kashikar ND, et al. Management of hepatocellular adenoma: comparison of resection, embolization and observation. HPB (Oxford). 2013;15:235-243.
Meyer C, Lisker-Melman M. Treatment of hepatic adenomatosis. Curr Hepatol Rep. 2015;14:139-143.
Chiche L, David A, Adam R, et al. Liver transplantation for adenomatosis: European experience. Liver Transpl. 2016;22:516-526.
Laumonier H, Rullier A, Saric J, Balabaud C, Bioulac-Sage P. Unexpected discovery of 2 cases of hepatocyte nuclear factor 1alpha-mutated infracentimetic adenomatosis. World J Gastroenterol. 2008;14:4830-4833.
Grazioli L, Federle MP, Ichikawa T, Balzano E, Nalesnik M, Madariaga J. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology. 2000;216:395-402.
Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics. 2001;21:877-892.
Lewin M, Handra-Luca A, Arrive L, et al. Liver adenomatosis: classification of MR imaging features and comparison with pathologic findings. Radiology. 2006;241:433-440.
Bioulac-Sage P, Rebouissou S, Thomas C, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740-748.
Bellanne-Chantelot C, Carette C, Riveline JP, et al. The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes. 2008;57:503-508.
Buhler H, Pirovino M, Akobiantz A, et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology. 1982;82:775-782.
Aseni P, Sansalone CV, Sammartino C, et al. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol. 2001;33:234-236.
Mariani AF, Livingstone AS, Pereiras RV Jr, van Zuiden PE, Schiff ER. Progressive enlargement of an hepatic cell adenoma. Gastroenterology. 1979;77:1319-1325.
Marks WH, Thompson N, Appleman H. Failure of hepatic adenomas (HCA) to regress after discontinuance of oral contraceptives. An association with focal nodular hyperplasia (FNH) and uterine leiomyoma. Ann Surg. 1988;208:190-195.
Torbenson M, Lee JH, Choti M, et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol. 2002;15:189-196.
Brander WL, Vosnides G, Ogg CS, West IE. Multiple hepatocellular tumours in a patient treated with oral contraceptives. Virchows Arch A Pathol Anat Histol. 1976;370:69-76.
Khan SS, Fink M, King S. Case report: liver adenomatosis presenting as multiple calcified masses. Clin Radiol. 1992;45:206-207.
Svrcek M, Jeannot E, Arrive L, et al. Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. Eur J Endocrinol. 2007;156:617-621.
Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg. 1994;129:712-717.
Dereure O, Guilhou JJ. Multifocal hepatocellular carcinoma presenting as prurigo: two cases. Br J Dermatol. 2000;143:1331-1332.
Yunta PJ, Moya A, San-Juan F, et al. [A new case of hepatic adenomatosis treated with orthotopic liver transplantation.]. Ann Chir. 2001;126:672-674.
Rebouissou S, Franconi A, Calderaro J, et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different β-catenin activity associated with liver tumor progression. Hepatology. 2016;64:2047-2061.
Hechtman JF, Abou Alfa GK, Stadler ZK, et al. Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. Hum Pathol. 2018. https://doi.org/10.1016/j.humpath.2018.08.004.